Innovations In Neuromodulation: Venture Capital Panel June 6, 2015 - - PowerPoint PPT Presentation

Tony Borowicz

VP, Business Development

Innovations In Neuromodulation: Venture Capital Panel

June 6, 2015

Batteries | Capacitors | Catheters | Stimulation Leads | Feedthroughs Device Enclosures & Cases | Device Headers | Device Assembly Advanced Coatings | Introducers | Orthopaedic Trays, Cases & Implants

Header Enclosure Stimulation Leads Battery

Greatbatch As A Core Partner

Feedthrough

3

Who We Serve

How We Partner

GB Ventures

Develops and commercializes high-value neural interface technology, components and systems for neuroscience and clinical applications Develops and manufactures complete medical devices, including active implantable medical devices for neuromodulation Designs and develops medical device technologies and system level platforms Designs and manufacturers medical devices and discrete technologies for CRM, neuromodulation, vascular,

• rthopaedic, and portable medical applications

Makes strategic investments in markets, products, or technologies aligned with Greatbatch business categories

• r adjacent growth opportunities

Segment Offering

R&D Neural Interface

Basic science & technology studies Clinical translational studies Applied science & technology studies

Develops advanced technologies and devices for Neuroscience & Neurostimulation research markets NeuroNexus powers the R&D leading to next-generation neurostimulation markets, indications, and products

Thin-film electrodes

Quality System Fully Integrated Manufacturing Facility Proven Development Platform Turn-key Medical Manufacturing

Device Development & Manufacturing

CCC is dedicated to the development & manufacturing of complete real-time medical systems including active implantable medical devices

• Fast prototyping
• Full product design &

development

• Testing & verification
• Low & medium

volume manufacturing

• IDE, PMA, & CE Mark

documentation

• Sensing
• Stimulation
• Communication
• Battery recharge
• Impedance measure
• FW download
• Other modules
• Class 7 & 8 clean

areas

• Complete IPG

assembly

• Packaging &

sterilization

• ISO 13485:2003

certified (BSI)

• FDA 21 CFR Part 820

and registered

System Platform R&D

QiG Group empowers the creative design, development and speed to market

• f new medical devices in strategic markets

Design & development of complete neurostimulation system platforms

• IPGs
• Leads
• Programmers
• Software
• Accessories

Design & Manufacturing

• Component, value-added-assembly & full system manufacturing
• FDA Registered Facility / Regulatory: ISO13485:2003, CMDCAS, AIMD & MDD

Greatbatch Medical is committed to the design and manufacture of critical technologies that enhance the reliability and performance of medical devices

Minority Equity Strategic Investment Philosophy

• $2 – 5M targeted investments
• 3 – 5 targeted deals per year
• Typically board observer seat
• < 20% ownership equity positions nor maintain controlling interest

Cardiac Neuromodulation Orthopaedics Vascular Portable Medical

GB Ventures

Strategic Investments

GB Ventures targets strategic investments in markets, products or technologies aligned with Greatbatch business categories or adjacent growth opportunities

GB Ventures

How We Invest

Investment Return

Cash Equity Innovations & IP Royalty, Additional Equity, Alternate Fields of Use Product Development Services NRE Funding Manufacturing Capabilities Exclusive Long Term Agreement Commercialization Avenues Exclusive Distribution Agreement

Creating a ‘Win – Win’ Partnership

• Equity investments
• Research
• Prototyping
• Component manufacturing

for clinical trials

GB Ventures

• Leads
• Batteries
• Feed throughs
• FDA experience
• Quality Systems
• Platform system reduces

time and risk to market

• Other Neurostimulation

indications

Early Stage Innovation Medical Device Components Medical Device Systems

Positioned for Neurostimulation Partnerships

Our Story

• One-stop shop for long-term strategic partnerships from

early stage investments through commercialization

• Multi-faceted mechanisms supporting:

› Investments › Research › Technology development › Clinical trials › Manufacturing

• History as world-class component supplier
• Next generation device development
• High volume manufacturing

Unique Partnership Opportunity in the Field of Neuromodulation. Leverage our Capital, Technologies, Components, Platforms & Manufacturing

Tony Borowicz

VP, Business Development

Innovations In Neuromodulation: Venture Capital Panel

June 6, 2015

Thank you!